Western Regional Medical Center
Western Regional Medical Center
News Article | July 13, 2017
PORTOLA VALLEY, Calif.--(BUSINESS WIRE)--TransMed7, LLC, today announced the appointment of Edgar D. Staren, MD, PhD, MBA, as TransMed7’s President as well as President of Martinet Medical, LLC, a new subsidiary Project Company among its portfolio, effective July 1, 2017. “Dr. Staren brings more than 20 years’ experience as a successful healthcare executive leading clinical programs, facilities, and biotechnology startups as well as operations management in both for-profit and not-for-profit arenas,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “In his new role, he will be responsible for taking our overall business strategy to the next level, as well as managing operations, quality, and financial performance for both TransMed7 and each of our Project Companies. Dr. Staren will also lead our efforts to substantially expand our presence in the greater Phoenix area and the Southwest U.S. market. We are fortunate to be able to add Dr. Staren’s leadership and experience to our mix, and look forward to the new impetus he brings to the growth of our business.” Most recently Dr. Staren was Professor of Surgery, VP and Executive Director for Cancer Services at Wake Forest University Baptist Health, and Deputy Director for Clinical Affairs of its Comprehensive Cancer Center where he fostered tremendous growth in cancer services, enhanced clinical efficiencies, and drove substantial increase in operating income. Immediately prior to this he served as CEO of Ashion PMed Management, LLC, and President of its subsidiary, Ashion Advanced Individual Medicine, LLC, both outgrowths of the Translational Genomic Research Institute (TGen) and now an affiliate of the City of Hope Comprehensive Cancer Center. A graduate of Loyola University School of Medicine, Dr. Staren received his surgical training at Rush University Medical Center and Cook County Hospitals; he remained at Rush as a faculty member where he held positions as Professor and Associate Dean. He subsequently was recruited as Professor and Chairman of Surgery at the Medical College of Ohio and Medical Director of the MCO Cancer Institute. He then served as SVP and Chief Medical Officer, Western Regional Medical Center CEO, and CEO of CTCA Medicine and Science before joining Ashion. Dr. Staren has been regularly listed in “Best Doctors in America” and “America’s Top Doctors for Cancer.” He is a member of numerous academic organizations including the American Surgical Association, the American Society of Clinical Oncology, the Society of Surgical Oncology and is a Past President of the American Society of Breast Surgeons. He has published nearly 300 scientific works including more than 150 manuscripts, 80+ abstracts, 45 book chapters, and 12 books. He has given more than 200 visiting professorships or invited lectures. “I feel most fortunate to be joining a remarkably talented team dedicated to bringing their combined expertise to bear in order to make a difference in the lives of patients in need,” says Dr. Staren. According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Staren has been a pioneer and strong advocate for the enhanced use of minimally invasive, image-guided procedures throughout his career. Along with his proven operational excellence, Dr. Staren brings his extensive experience with the latest diagnostic and treatment advances to further advance TransMed7’s prime objective of improving each patient’s treatment, care and quality of life through practical translation of new capabilities and concepts into our pipeline of transformational devices.” TransMed7, LLC is a medical and technology based organization focused on the highly efficient development of innovative, minimally invasive medical devices aimed at providing new solutions for doctors and their patients. With particular expertise in both oncologic and cardiovascular disease, TransMed7 and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices that are expected to be market leaders in their targeted fields of medicine. TransMed7 accomplishes this through application of a wholly new approach in its business plan and structure, enabling these new transformational technologies from rapid development through commercial manufacturing or where appropriate, handoff to our Strategic Partners. For more information about TransMed7, please visit our website at www.transmed7.com.
News Article | August 15, 2017
OMAHA, Neb., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Werner Enterprises, Inc. (NASDAQ:WERN), one of the nation's largest transportation and logistics companies, announced that Michael L. Gallagher has joined the Company’s Board of Directors effective today. Duane K. Sather, director since 2006, has retired from the Board of Directors. “On behalf of everyone at Werner Enterprises and the Board of Directors, I would like to thank Duane Sather for his contributions to the success of the Company and his years of valued service as a director,” said Clarence L. Werner, Executive Chairman. Mr. Gallagher is Chairman Emeritus of the law firm Gallagher & Kennedy in Phoenix, Arizona. He has held this position since 2001. Mr. Gallagher served as President of Gallagher & Kennedy from 1978 through 2000. Mr. Gallagher is a member of the board of directors of Pinnacle West Capital Corporation, a NYSE listed company; Cancer Treatment Centers of America, Western Regional Medical Center; Arizona Public Service Company; and the Peter Kiewit Foundation. He previously served as a director of AMERCO, the parent company of U-Haul International, Inc., and Action Performance, a NASDAQ company, and was a former advisory board member of AMEC, a multinational company headquartered in Europe. Mr. Gallagher has 40 years of experience as legal counsel to numerous public and private corporations. “His knowledge and experience from participating on the boards of other publicly-traded and private companies as well as his extensive experience addressing corporate governance matters will provide valuable perspective to the Company,” said Mr. Werner. Werner Enterprises, Inc. was founded in 1956 and is a premier transportation and logistics company, with coverage throughout North America, Asia, Europe, South America, Africa and Australia. Werner maintains its global headquarters in Omaha, Nebraska and maintains offices in the United States, Canada, Mexico, China and Australia. Werner is among the five largest truckload carriers in the United States, with a diversified portfolio of transportation services that includes dedicated; medium-to-long haul, regional and expedited van; and temperature-controlled. The Werner Logistics portfolio includes truck brokerage, freight management, intermodal, international and final mile services. International services are provided through Werner's domestic and global subsidiary companies and include ocean, air and ground transportation; freight forwarding; and customs brokerage. Werner Enterprises, Inc.’s common stock trades on the NASDAQ Global Select MarketSM under the symbol “WERN”. For further information about Werner, visit the company’s website at www.werner.com.
Zarogoulidis P.,Aristotle University of Thessaloniki |
Lampaki S.,Aristotle University of Thessaloniki |
Francis Turner J.,Western Regional Medical Center |
Huang H.,Shanghai University |
And 3 more authors.
Oncology Letters | Year: 2014
Mammalian target of rapamycin (mTOR) is a protein serine/threonine kinase that was initially identified as the cellular target of rapamycin. This kinase regulates cell growth, proliferation, motility and survival, as well as the gene transcription and protein synthesis that are activated in response to hormones, growth factors and nutrients. Results from preclinical studies have indicated that factors antagonizing the mTOR pathway exert an antitumor effect on lung cancer. Furthermore, primary clinical trials of mTOR inhibitors have demonstrated that the inhibitors may be effective against lung carcinoma. The present study explores the association between mTOR and lung carcinogenesis and describes the clinical trials of mTOR inhibitors. © 2014, Spandidos Publications. All rights reserved.
PubMed | Helfgott Research Institute, Denver Naturopathic Clinic, Tahoma Clinic, Western Regional Medical Center and 4 more.
Type: Journal Article | Journal: Integrative cancer therapies | Year: 2016
Naturopathic oncology is a relatively new and emerging field capable of providing professional integrative or alternative services to cancer patients. Foundational research is critical to identify topics in the clinical and research development of naturopathic oncology for future growth of the field.This study implements a modified Delphi protocol to develop expert consensus regarding ethics, philosophy, and research development in naturopathic oncology.The modified protocol implements a nomination process to select a panel of 8 physicians and to assist in question formulation. The protocol includes an in-person discussion of 6 questions with multiple iterations to maintain the concept of the Delphi methodology as well as a postdiscussion consensus survey.The protocol identified, ranked, and established consensus for numerous themes per question. Underlying key topics include integration with conventional medicine, evidence-based medicine, patient education, patient safety, and additional training requirements for naturopathic oncologists.The systematic nomination and questioning of a panel of experts provides a foundational and educational resource to assist in clarification of clinical ethics, philosophy, and research development in the emerging field of naturopathic oncology.
PubMed | University of Pennsylvania, Germans Trias i Pujol Health science Institute and Hospital, Yale University, Western Regional Medical Center and 5 more.
Type: Journal Article | Journal: The Lancet. Oncology | Year: 2016
Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with potent preclinical activity against ALK mutants resistant to crizotinib and other ALK inhibitors. We aimed to assess brigatinib in patients with advanced malignancies, particularly ALK-rearranged NSCLC.In this ongoing, single-arm, open-label, phase 1/2 trial, we recruited patients from nine academic hospitals or cancer centres in the USA and Spain. Eligible patients were at least 18 years of age and had advanced malignancies, including ALK-rearranged NSCLC, and disease that was refractory to available therapies or for which no curative treatments existed. In the initial dose-escalation phase 1 stage of the trial, patients received oral brigatinib at total daily doses of 30-300 mg (according to a standard 3+3 design). The phase 1 primary endpoint was establishment of the recommended phase 2 dose. In the phase 2 expansion stage, we assessed three oral once-daily regimens: 90 mg, 180 mg, and 180 mg with a 7 day lead-in at 90 mg; one patient received 90 mg twice daily. We enrolled patients in phase 2 into five cohorts: ALK inhibitor-naive ALK-rearranged NSCLC (cohort 1), crizotinib-treated ALK-rearranged NSCLC (cohort 2), EGFRBetween Sept 20, 2011, and July 8, 2014, we enrolled 137 patients (79 [58%] with ALK-rearranged NSCLC), all of whom were treated. Dose-limiting toxicities observed during dose escalation included grade 3 increased alanine aminotransferase (240 mg daily) and grade 4 dyspnoea (300 mg daily). We initially chose a dose of 180 mg once daily as the recommended phase 2 dose; however, we also assessed two additional regimens (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg) in the phase 2 stage. four (100% [95% CI 40-100]) of four patients in cohort 1 had an objective response, 31 (74% [58-86]) of 42 did in cohort 2, none (of one) did in cohort 3, three (17% [4-41]) of 18 did in cohort 4, and five (83% [36-100]) of six did in cohort 5. 51 (72% [60-82]) of 71 patients with ALK-rearranged NSCLC with previous crizotinib treatment had an objective response (44 [62% (50-73)] had a confirmed objective response). All eight crizotinib-naive patients with ALK-rearranged NSCLC had a confirmed objective response (100% [63-100]). Three (50% [95% CI 12-88]) of six patients in cohort 5 had an intracranial response. The most common grade 3-4 treatment-emergent adverse events across all doses were increased lipase concentration (12 [9%] of 137), dyspnoea (eight [6%]), and hypertension (seven [5%]). Serious treatment-emergent adverse events (excluding neoplasm progression) reported in at least 5% of all patients were dyspnoea (ten [7%]), pneumonia (nine [7%]), and hypoxia (seven [5%]). 16 (12%) patients died during treatment or within 31 days of the last dose of brigatinib, including eight patients who died from neoplasm progression.Brigatinib shows promising clinical activity and has an acceptable safety profile in patients with crizotinib-treated and crizotinib-naive ALK-rearranged NSCLC. These results support its further development as a potential new treatment option for patients with advanced ALK-rearranged NSCLC. A randomised phase 2 trial in patients with crizotinib-resistant ALK-rearranged NSCLC is prospectively assessing the safety and efficacy of two regimens assessed in the phase 2 portion of this trial (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg).ARIAD Pharmaceuticals.
PubMed | Aristotle University of Thessaloniki, Cancer Treatment Centers of America, Western Regional Medical Center and U.S. National Institutes of Health
Type: Journal Article | Journal: Case reports in oncology | Year: 2014
A 31-year-old white male with a known history of colon carcinoma was referred to the Interventional Pulmonary service for right lower lobe infiltrates and mucous plugging on computed tomography with concern for pneumonia. Bronchoscopy was performed revealing a broad based mass completely obstructing the bronchus intermedius. It was possible to pass a probe into the right lower lobe, and subsequent photoablation and mechanical debulking revealed that the mass was arising near the origin of the superior basal segment of the right lower lobe (RB6) and could be resected. Pathology confirmed this was consistent with the patients known primary colon carcinoma. The potential for endobronchial metastasis in patients with colorectal carcinoma should be investigated in those patients with new or worsening pulmonary symptoms and signs.
PubMed | University of Würzburg, Aristotle University of Thessaloniki, Goethe University Frankfurt, U.S. Army and 5 more.
Type: | Journal: OncoTargets and therapy | Year: 2015
Lung cancer remains the leading cause of death in cancer patients. Severe treatment side effects and late stage of disease at diagnosis continue to be an issue. We investigated whether local treatment using 2-diethylaminoethyl-dextran methyl methacrylate copolymer with p53 (DDMC-p53) with or without cisplatin and/or microwave ablation enhances disease control in BALBC mice. We used a Lewis lung carcinoma cell line to inoculate 140 BALBC mice, which were divided into the following seven groups; control, cisplatin, microwave ablation, DDMC-p53, DDMC-p53 plus cisplatin, DDMC-p53 plus microwave, and DDMC-p53 plus cisplatin plus microwave. Microwave ablation energy was administered at 20 W for 10 minutes. Cisplatin was administered as 1 mL/mg and the DDMC-p53 complex delivered was 0.5 mL. Increased toxicity was observed in the group receiving DDMC-p53 plus cisplatin plus microwave followed by the group receiving DDMC-p53 plus cisplatin. Infection after repeated treatment administration was a major issue. We conclude that a combination of gene therapy using DDMC-p53 with or without cisplatin and microwave is an alternative method for local disease control. However, more experiments are required in a larger model to identify the appropriate dosage profile.
PubMed | Cancer Treatment Centers of America, Western Regional Medical Center and Drexel University
Type: Journal Article | Journal: Case reports in oncology | Year: 2014
Cyclophosphamide is an alkylating agent widely used in antineoplastic and immunosuppressive therapies. Symptomatic hyponatremia can be a rare but life-threatening complication in patients treated with cyclophosphamide.We report 2 patients who presented with severe acute hyponatremic encephalopathy after receiving their first cycles of a low-dose cyclophosphamide-containing regimen for breast cancer. In case 1, a 58-year-old female received the combination of docetaxel and cyclophosphamide, and in case 2, a 56-year-old female received the combination of doxorubicin and cyclophosphamide. Both patients recovered after correction of their serum sodium concentration without neurological deficits. Future cycles of chemotherapy were well tolerated without recurrence of hyponatremia after cyclophosphamide was discontinued from the respective regimens.Clinicians must always keep in mind that acute hyponatremic encephalopathy can be induced by low-dose cyclophosphamide.
News Article | December 6, 2016
New findings that may impact patient care to be presented at annual World Conference on Lung Cancer (PHOENIX, Arizona - Dec. 6, 2016) - Lung cancer-based studies conducted at Cancer Treatment Centers of America® (CTCA) will be presented at the 17th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Vienna, Austria, Dec. 4-7. These studies represent research conducted by members of the research team at Western Regional Medical Center led by Dr. Glen Weiss as they search for treatment options for varying types of lung cancer. "Lung cancer remains the leading cause of cancer-related death, and it is critical we commit research to ways in which we can identify new avenues for drug targets that may help more of these patients," said Dr. Weiss, Director of Clinical Research and Phase I and Phase II clinical trials at CTCA® at Western Regional Medical Center (Western). "It's an honor to be included among this year's participants at the World Conference on Lung Cancer," Weiss added. "It is our hope that this shared knowledge and research will benefit many lung cancer patients worldwide." More than 224,000 Americans will be diagnosed this year with some type of lung cancer, and more than 158,000 will succumb to this disease in 2016, making it by far the leading cause of cancer-related death in the U.S. For more details on these studies, visit: http://library. . For more information about CTCA trials currently available, visit http://www. , email WesternTrials@ctca-hope.com or call 888-841-9129. Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-informed supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.
Quan W.D.Y.,Western Regional Medical Center |
Quan F.M.,Loma Linda University
Cancer Biotherapy and Radiopharmaceuticals | Year: 2014
Outpatient daily intravenous infusions of interleukin-2 (IL-2) have been developed to maintain anticancer activity and decrease toxicity of this agent against kidney cancer. Lymphokine activated killer cell (LAK) numbers are increased with these IL-2 schedules. Famotidine may enhance the LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes. Fifteen patients with metastatic clear cell kidney cancer received IL-2 18 million IU/M2 intravenously over 15-30 minutes preceded by famotidine 20 mg IV daily for 3 days for 6 consecutive weeks as outpatients. Cycles were repeated every 8 weeks. Patient characteristics were seven males/eight females, median age 59 (range: 28-70), median Eastern Cooperative Oncology Group (ECOG) performance status-1; common metastatic sites were lungs (14), lymph nodes (9), liver (4), bone (4), and pancreas (4). Prior systemic therapies were oral tyrosine kinase inhibitor (8), IL-2 (6), and mTor inhibitor (2). Most common toxicities were rigors, arthralgia/myalgia, nausea/emesis, fever, and hypotension. All episodes of hypotension were reversible with intravenous fluid. No patients required hospitalization due to toxicity. One complete response (7%) and four partial responses (26%) were seen (total response rate=33%; 95% confidence interval: 15%-59%). Responses occurred in the lungs, liver, lymph nodes, and bone. Outpatient intravenous IL-2 with famotidine has activity in metastatic clear cell kidney cancer. © Mary Ann Liebert, Inc.